CFTR and cystic fibrosis: The US Food and Drug Administration-approved triple CFTR modulator therapy, ETI has shown significant therapeutic benefit in people with CF, with an approximate 10–14% improvement in percentage predicted forced expiratory volume in 1 s (FEV1 % pred) and a 60% reduction in exacerbations [6, 20].